Trial
NCT02674555
A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Astellas Pharma Global Development, Inc.
Collaborators
—
Condition
Epidermal Growth Factor Receptor (EGFR) Mutations
Intervention
radio-labeled naquotinib
Why stopped
Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-07-28